A decade of oncology drugs aimed at the receptor, and why most of them stopped

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
The association between IGF-1 signalling and cancer led several companies to develop antibodies that block the IGF-1 receptor. Figitumumab reached phase 3 in non-small-cell lung cancer and was stopped in 2010 for lack of benefit and excess deaths in the treatment arm; ganitumab failed in pancreatic cancer; dalotuzumab and cixutumumab failed in colorectal and other cancers. Tumours compensated through the insulin receptor, which the antibodies do not block and which IGF-2 activates, and the drugs raised blood glucose and growth hormone. One receptor antibody, teprotumumab, later found a use outside cancer, in thyroid eye disease, approved in 2020.

The programmes

Preclinical work showed IGF-1 receptor signalling protected tumour cells from chemotherapy, and early trials in Ewing sarcoma showed responses in a minority. Phase 3 trials in common cancers followed, adding the antibody to standard chemotherapy. The lung cancer trial of figitumumab enrolled hundreds of patients before an interim analysis showed more deaths with the antibody.

By 2014 most programmes had been discontinued.

Why they failed

The insulin receptor, especially its A isoform, is expressed on tumours and signals through the same pathway; blocking the IGF-1 receptor alone leaves it open, and the rise in insulin that follows from the glucose effects feeds it. Hybrid receptors complicate the picture further. No biomarker identified the patients who would benefit. The biology that made the target attractive also made it redundant.

The failures are a standard case study in why pathway redundancy defeats single-target drugs.

Why it is here

Because it is the largest body of human data on blocking the receptor that IGF-1 LR3 activates, and because it describes what that receptor does in tumours. It describes no use of the pack.

IGF-1 LR3 is supplied by REVIVE LAB UAE for laboratory research use only, with identity and purity documented for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
IGF-1 LR3 Pack1 mgAED 650In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The programmes?

Preclinical work showed IGF-1 receptor signalling protected tumour cells from chemotherapy, and early trials in Ewing sarcoma showed responses in a minority. Phase 3 trials in common cancers followed, adding the antibody to standard chemotherapy. The lung cancer trial of figitumumab enrolled hundreds of patients before an interim analysis showed more deaths with the antibody.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

IGF-1 LR3 Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.